Myriad Genetics
MYGN announced today that a study published in the British Journal of
Cancer demonstrated the ability of the Company's Homologous Recombination
Deficiency (HRD) Assay to detect loss of DNA repair in ovarian tumors. The
study, entitled, "Patterns of Genomic Loss of Heterozygosity Predict
Homologous Recombination Repair Defects in Epithelial Ovarian Cancer,"
confirmed, with highly statistically significant results, the relationship
between Myriad's HRD score and tumors deficient in DNA repair.
"By measuring the HRD score in tumor samples we expect to be able to predict
patient response to therapeutic agents that exploit deficiencies in DNA
repair," said Jerry Lanchbury Ph.D., Chief Scientific Officer of Myriad
Genetics Inc. "Through this best-in-class test we intend to provide patients
and their healthcare providers with critical information regarding response to
platinum drugs or PARP inhibitors across multiple cancers including breast,
ovarian and other cancers."
Researchers at M.D. Anderson Cancer Center, University of California, San
Francisco, University of Pittsburgh, University of British Colombia, Royal
College of Surgeons in Ireland, and Myriad Genetics generated HRD scores in
639 ovarian tumor samples as well as 57 breast and pancreatic cancer cell
lines. The data demonstrated that a high HRD score is highly correlated (p =
1.0 x 10^-48) with tumor deficiency in DNA repair.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in